ClinicalTrials.gg
CompletedNCT06095427Updated Oct 19, 2026

A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection

A Phase 1 interventional study of LY06006 (Denosumab Biosimilar) and US-Prolia (Denosumab) in Healthy, sponsored by Shandong Boan Biotechnology Co., Ltd. Completed at 2 sites in Germany. Open to male participants aged 28 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Shandong Boan Biotechnology Co., Ltd (part of Luye Pharma Group Ltd.) · Phase 1, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.
  • Registered 2 years 1 month after the study started (first participant enrolled Mar 2021, registered May 2023).
Updated Oct 19, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
28 Years to 65 Years
Sex
Male
01

Study summary

This trial is a randomized, double-blind, three-arm, parallel-group, pharmacokinetic study. The purpose of this study is to demonstrate pharmacokinetic (PK) similarity and to compare safety, immunogenicity and pharmacodynamics (PD) between the test product L06006 and the reference products US-Prolia and EU-Prolia in healthy male subjects. A total of 300 healthy male subjects aged 28 to 65 years (both inclusive) will be randomized 1:1:1 to receive a single subcutaneous (s.c.) injection of either LY06006 or US-Prolia or EU-Prolia on Day 1 and then be followed for 36 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shandong Boan Biotechnology Co., Ltd is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

First submitted after Shandong Boan Biotechnology Co., Ltd became part of Luye Pharma Group Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males aged 28 - 65 years, both inclusive;
  2. (BMI) between 18 to \< 30 kg/m2 and body weight of 60 - 90 kg (both inclusive);
  3. Subjects must give written before any assessment is performed and has to understand the study and must be willing to follow and complete all the test procedures;
  4. Clinically acceptable physical exams and laboratory tests (blood hematology, blood chemistry, coagulation, urinalysis) and no history or evidence of any medical disorder that would pose a risk to subject safety or interfere with study evaluations or procedures;
  5. Available for long term clinical assessments (36 weeks post-dose) for PK/PD and immunogenicity assessments;
  6. Subjects and their female partners who are of must be using 2 forms of (1 of which is a highly effective method† and 1 must be a barrier method‡) or abstain from sexual intercourse with a female partner (acceptable only if it is the subject's usual form of birth control/lifestyle choice) starting at Day -1 and throughout the study period and for at least 1 month after the end of EoS Visit. A condom is required to be used also by vasectomized men to prevent delivery of the drug via seminal fluid.

Highly effective forms of birth control include (i.e., less than 1% failure rate per year when used consistently and correctly):

  • hormonal contraception, i.e., oral, injectable or implantable hormonal contraceptives for the female partner (Note: Not all oral contraception methods have a low failure rate.).
  • hormonal or non-hormonal intrauterine device (IUD), established IUD (loop) or intrauterine system for the female partner.
  • the subject has undergone effective surgical sterilization before he entered the study.
  • the subject's female partner has undergone effective surgical sterilization before the subject entered the clinical trial and she is the sole sexual partner of the subject during the study.

Acceptable methods of surgical sterilization are:

  • Surgical bilateral oophorectomy for the female partner (with or without hysterectomy) at least 6 weeks before the SCR Visit.
  • Hysterectomy for the female partner at least 6 weeks before the SCR Visit.
  • Bilateral tubal ligation for the female partner at least 6 weeks before the SCR Visit.

Barrier methods of birth control:

  • Condom without spermicidal foam / gel / film / cream / suppository or fat- or oil-containing lubricant.
  • Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam / gel / film / cream / suppository for the female partner.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with prior exposure to denosumab (Prolia, Xgeva, or biosimilar denosumab);
  2. Use of any other monoclonal antibodies or fusion proteins within the 3 months or 5 half-lives (whatever is longer) before the date of administration of the IMP;
  3. Subjects being on a special diet or with significant weight loss from a weight reduction diet (e.g., more than approx. 5 kg within 1 month) before the SCR Visit or unwilling to maintain the same weight for the duration of the study;
  4. Donation or loss of ≥ 500 mL of blood within 8 weeks prior to dosing, or longer if required by local regulation. Plasma donation within 28 days prior to dosing;
  5. Diseases and conditions that affect bone metabolism e.g., osteoporosis, hypo/hyper-parathyroidism (excluding isolated deviations of parathormone assessed as not ); hypo-/hyperthyroidism, Cushing's syndrome, malabsorption syndromes, rheumatoid arthritis, psoriatic arthritis, osteomalacia, bone fractures within 6 months, or any to denosumab therapy;
  6. Vitamin D deficiency (serum 25-hydroxy vitamin D \< 20 ng/mL). For subjects with vitamin D deficiency, a single attempt at oral replenishment with re-evaluation prior to randomization is permitted (see Section 5.5);
  7. Subjects with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg and / or pulse \< 50 or > 90 bpm (mean of triplicate measurements. Subjects with pulse rate between 45 and 50 bpm (inclusive) may be enrolled provided they have a normal thyroid function, no clinical symptoms associated with the bradycardia and no apparent signs of other diseases causing bradycardia (e.g., cardiovascular disease);
  8. Subjects with abnormal ECGs ( > 450 ms, signs of ischemia, sinus tachycardia [heart rate, HR > 90] or sinus bradycardia [HR \< 50], ventricular conduct delay [QRS > 120 ms] or others) which, in the judgment of the Investigator or any of the Sub-Investigators, may be clinically relevant. Subjects with heart rate between 45 and 50 bpm (inclusive) may be enrolled provided they have a normal thyroid function, no clinical symptoms associated with the bradycardia and no apparent signs of other diseases causing bradycardia (e.g., cardiovascular disease). Potential cardiovascular disease resulting in bradycardia should be excluded by further investigations on the discretion of the Investigator;
  9. Any clinically relevant laboratory findings that, in the opinion of the Investigator, would preclude inclusion in the trial; subjects with creatinine above (ULN) or liver enzymes ( [ALT], aspartate aminotransferase [AST]) 1.5-fold above ULN will be excluded;
  10. Subject presents with any psychiatric disorder, which may prevent the subject from completing the study or interfere with the interpretation of the study results;
  11. Subjects with current or a history of clinically significant (or "serious") skin infections or skin disorders;
  12. Subject has a history or presence of anemia or coagulopathy;
  13. Significant changes in physical activity during the 6 months before IMP administration or constant levels of intense physical exercise;
  14. Positive test results for surface antigen (HbsAg), anti-hepatitis B core (anti-HBc) antibodies indicative of active hepatitis, optionally Hepatitis B surface antibody (anti-HBS), hepatitis A virus antibodies (immunoglobulin M [IgM]), virus (HCV) antibodies and / or (HIV) type-1 and / or type-2 antibodies at the SCR Visit;
  15. Use of any prescription drug or any over-the-counter (OTC) drug within the 2 weeks (or less than 5 x the half-life of that medication, whichever is longer) including herbal supplements, or prescribed/ non-prescribed marijuana derivatives before the date of administration of the IMP (excluding localized use not intended to have systemic action and occasional use of paracetamol of up to 2 g per day), which, in the judgment of the Investigator or Sub-Investigators, may affect participation in this clinical study. Vitamins, minerals and nutritional supplements may be taken at the discretion of the Investigator;
  16. Prior use of any medications that may affect bone turnover within 12 months of IMP administration and for the duration of the study. This includes medications such as, but not limited to: bisphosphonates, fluoride, or selective estrogen receptor modulator, such as ralaxofene, calcitonin, strontium, parathyroid hormone or derivatives, supplemental vitamin D [> 1000 IU/day], except for the potential vitamin D replenishment after SCR, glucocorticosteroids, anabolic steroids, calcitriol, diuretics. Current use of anti-angiogenic drugs;
  17. Receiving or has received any drug (or is currently using an investigational device) within 60 days before receiving IMP, or at least 10 times the respective elimination half-life (whichever period is longer) and for the duration of the study;
  18. Men with partners who are pregnant or planning to become pregnant while the subject is on study until through at least 1 month after the end of the study;
  19. Intent to donate sperm during the study through at least 1 month after the end of the study;
  20. Unwilling or unable to limit alcohol consumption throughout the course of the study. Alcohol is prohibited 24 hours prior to each visit in the clinical and throughout confinement. Alcohol is also limited to no more than 168 g pure alcohol per week (10 g pure alcohol = 250 mL of beer [5%] or 35 mL of spirits [35%] or 100 mL of wine [12%]) during the outpatient period.;
  21. Positive urine screen for alcohol and/or drugs with a high potential for abuse at SCR or Day -1;
  22. Any other condition that might reduce the chance of obtaining data required by protocol or that might compromise the ability to give truly and/or comply with study procedures;
  23. Osteonecrosis of the jaw (ONJ) or risk factors for ONJ such as invasive dental procedures (e.g., tooth extraction, dental implants, oral surgery in the past 6 months), or planned invasive dental procedure during the study; poor oral hygiene, periodontal, and/or pre-existing dental disease;
  24. Subject with known to denosumab or any monoclonal /or polyclonal antibodies or previously received denosumab treatment or to any of the of the IMPs;
  25. Known allergies, hypersensitivity, or intolerance to protein-based therapies or to any ingredients (including excipients) of the additional medication (vitamin D, in case replenishment is given) or with a history of any significant drug allergy (e.g., anaphylaxis, hepatotoxicity, immune-mediated thrombocytopenia or anemia) including latex;
  26. Corrected serum calcium of \< Lower Limit of Normal (LLN) or > ULN at SCR;
  27. Individuals with history of tuberculosis or diagnosed with active or latent tuberculosis by interview or interferon-gamma release assay;
  28. Vaccinations must be completed 6 weeks prior to dosing in case multiple vaccinations are required and no further vaccinations until the EoS. COVID-19 related vaccinations should not be done within at least 3 weeks prior to SCR and until 3 weeks after dosing. COVID-19 vaccinations should not be done or be planned from 2 days before or on the same day as any ambulatory visits;
  29. Participants who smoke more than 10 cigarettes per day or consume equivalent nicotine substitutes, including e-cigarettes or inability to refrain from smoking during the in-house period;
  30. Any disease or condition that in the opinion of Investigator, may affect the patient safety or the study results;
  31. Subject has a positive test result for SARS-CoV-2 in RT-PCR testing before randomization;
  32. Subject has clinical signs and symptoms consistent with COVID-19, e.g., fever, dry cough, dyspnea, sore throat, fatigue or confirmed infection by appropriate laboratory test within the last 30 days prior to SCR or on admission;
  33. Subject who had severe course of COVID-19 (i.e., hospitalization, extracorporeal membrane oxygenation (ECMO), and/or mechanically ventilated);
  34. Vulnerable subjects (i.e., persons under any administrative or legal supervision or persons kept in detention);
  35. Subjects who are employees of Sponsor, clinical research organization (CRO) or who is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other site staff or relative thereof directly involved in the conduct of the clinical study;
  36. Subjects who are not able to read, speak and understand the German language.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    LY06006

    60 mg LY006006

    Biological: LY06006 (Denosumab Biosimilar)

  • Active comparator
    US-Prolia

    60 mg US-Prolia

    Biological: US-Prolia (Denosumab)

  • Active comparator
    EU-Prolia

    60 mg EU-Prolia

    Biological: EU-Prolia

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-t

    Area under the concentration-time curve (AUC) from time zero to last quantifiable concentration (AUC0-t)

    Time frame: Day 1 until Day 253

  2. Cmax

    Maximum serum concentration (Cmax)

    Time frame: Day 1 until Day 253

  3. AUC0-inf

    Area under the concentration-time curve (AUC) from time zero to infinity (AUC0-inf) AUC0-inf = AUC from time zero to the last quantifiable concentration (AUC0-t) + last observed concentration (Ct) / terminal rate constant (λz)

    Time frame: Day 1 until Day 253

Secondary outcomes

  1. tmax

    Time corresponding to the occurrence of Cmax (tmax)

    Time frame: Day 1 until Day 253

  2. t½

    Apparent terminal half-life calculated by ln2/λz (t½)

    Time frame: Day 1 until Day 253

  3. CL/F

    Apparent total body clearance (CL/F)

    Time frame: Day 1 until Day 253

  4. Vd

    Apparent volume of distribution based on the terminal phase (Vd)

    Time frame: Day 1 until Day 253

  5. λz

    Terminal rate constant (λz)

    Time frame: Day 1 until Day 253

  6. %AUCex

    Percentage of AUC0-inf obtained by extrapolation (%AUCex)

    Time frame: Day 1 until Day 253

  7. Incidence of adverse events (AEs) and serious AEs (SAEs)

    Incidence of adverse events (AEs) and serious AEs (SAEs)

    Time frame: Day 1 until Day 253

  8. blood pressure

    supine blood pressure \[BP\]

    Time frame: Day 1 until Day 253

  9. pulse rate

    pulse rate

    Time frame: Day 1 until Day 253

  10. body temperature

    tympanic body temperature

    Time frame: Day 1 until Day 253

  11. Clinical laboratory tests

    Clinical laboratory tests (hematology, clinical chemistry and urinalysis)

    Time frame: Day 1 until Day 253

  12. Physical examinations

    Physical examinations

    Time frame: Day 1 until Day 253

  13. Local tolerance

    Local tolerance assessed by the Investigator using the Injection site reaction (ISR) Score

    Time frame: Day 1 until Day 253

  14. Immunogenicity Endpoints

    Immunogenicity (ADA and Nab)

    Time frame: Day 1 until Day 253

  15. AUEC0-t (S-CTX)

    Area under S-CTX percent inhibition-time curve from time zero to last quantifiable concentration (AUEC0-t)

    Time frame: Day 1 until Day 253

  16. AUEC0-16w (S-CTX)

    Area under S-CTX percent inhibition-time curve from time zero to Day 113 (i.e., 16 weeks) (AUEC0-16w)

    Time frame: Day 1 until Day 113

  17. Imax (S-CTX)

    Maximum percent inhibition (Imax)

    Time frame: Day 1 until Day 253

  18. TImax (S-CTX)

    Time to reach maximum percent inhibition (TImax)

    Time frame: Day 1 until Day 253

07

Study locations

2 sites
  • Parexel International GmbH, Early Phase Clinical Unit Berlin
    Berlin, 14050, Germany
  • CTC North GmbH & Co KG
    Hamburg, 20251, Germany
08

References and documents

Publications

  • Fuhr R, Sun X, Wang X, Dong Y, Tai J, Zhou M, Dou C. A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects. Expert Opin Drug Metab Toxicol. 2024 Nov 24:1-9. doi: 10.1080/17425255.2024.2432673. Online ahead of print. PubMed 39582128 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Mar 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2023
First posted
Oct 23, 2023
StartActual
Mar 9, 2021
Primary completionActual
Mar 14, 2023
CompletionActual
Mar 14, 2023
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 39582128 ↗
Oct 19, 2026
Sponsor
Luye Pharma Group Ltd.→Shandong Boan Biotechnology Co., Ltd
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 39582128 ↗
    Sponsor Luye Pharma Group Ltd.→Shandong Boan Biotechnology Co., Ltd
    + 4 other changes: identifiers, verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06095427
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Mar 9, 2021
Primary completion
Mar 14, 2023
Completion
Mar 14, 2023
Last update
Oct 19, 2026

Study contacts

R Fuhr, MD
principal investigator · Parexel

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY06006

Start the discussion